Halozyme Therapeutics Inc (HALO)

[maumar]

I think melanoma is the second largest indication and together with RCC about 50% of opdivo's sales. Because of the recent positive developments (Ocrevus phase 3 start, SC Efga phase 3 positive results and Opdivo phase 3 start in melanoma), we now have some visibility into 4 potential approvals for Enhanze products: SC Efga, SC Tecentriq, SC Opdivo and SC Ocrevus in the next 3 years, hopefully the first one will be in 18 months. All of the above plus the recent new deal I am guessing are the reasons for the strong stock action in the past couple of weeks. The XBI going from $80 to $93 did not hurt either. It appears sentiment is finally turning.